CONTEXT: Although paclitaxel is one of the most commonly used drugs to treat breast, ovarian, and lung cancers, little is known about the impact of paclitaxel-induced peripheral neuropathy (PIPN) on cancer survivors. OBJECTIVES: The purposes of this study were to evaluate for differences in demographic and clinical characteristics as well as measures of sensation, balance, upper extremity function, perceived stress, symptom burden, and quality of life (QOL) between survivors who received paclitaxel and did (n = 153) and did not (n = 58) develop PIPN. METHODS: Pain characteristics associated with PIPN are described in detail. Both subjective and objective measures were used to evaluate the impact of PIPN. RESULTS: Survivors with PIPN were significantly older, had a higher body mass index, and a worse comorbidity profile. The duration of PIPN was almost four years, and pain scores were in the moderate range. Compared with survivors without PIPN, survivors with PIPN had a higher number of upper and lower extremity sites that had lost light touch, cold, and pain sensations. Survivors with PIPN had worse upper extremity function, more problems with balance, a higher symptom burden, and higher levels of perceived stress. In addition, survivors with PIPN had worse QOL scores particularly in the domain of physical functioning. CONCLUSION: The findings from this large descriptive study are the first to document the impact of PIPN on survivors' symptom burden, functional status, and QOL.
CONTEXT: Although paclitaxel is one of the most commonly used drugs to treat breast, ovarian, and lung cancers, little is known about the impact of paclitaxel-induced peripheral neuropathy (PIPN) on cancer survivors. OBJECTIVES: The purposes of this study were to evaluate for differences in demographic and clinical characteristics as well as measures of sensation, balance, upper extremity function, perceived stress, symptom burden, and quality of life (QOL) between survivors who received paclitaxel and did (n = 153) and did not (n = 58) develop PIPN. METHODS:Pain characteristics associated with PIPN are described in detail. Both subjective and objective measures were used to evaluate the impact of PIPN. RESULTS: Survivors with PIPN were significantly older, had a higher body mass index, and a worse comorbidity profile. The duration of PIPN was almost four years, and pain scores were in the moderate range. Compared with survivors without PIPN, survivors with PIPN had a higher number of upper and lower extremity sites that had lost light touch, cold, and pain sensations. Survivors with PIPN had worse upper extremity function, more problems with balance, a higher symptom burden, and higher levels of perceived stress. In addition, survivors with PIPN had worse QOL scores particularly in the domain of physical functioning. CONCLUSION: The findings from this large descriptive study are the first to document the impact of PIPN on survivors' symptom burden, functional status, and QOL.
Authors: S E Jones; J Erban; B Overmoyer; G T Budd; L Hutchins; E Lower; L Laufman; S Sundaram; W J Urba; K I Pritchard; R Mennel; D Richards; S Olsen; M L Meyers; P M Ravdin Journal: J Clin Oncol Date: 2005-08-20 Impact factor: 44.544
Authors: Meredith A Wampler; Kimberly S Topp; Christine Miaskowski; Nancy N Byl; Hope S Rugo; Kate Hamel Journal: Arch Phys Med Rehabil Date: 2007-08 Impact factor: 3.966
Authors: Antoinetta J M Beijers; Floortje Mols; Vivianne C G Tjan-Heijnen; Catharina G Faber; Lonneke V van de Poll-Franse; Gerard Vreugdenhil Journal: Acta Oncol Date: 2014-11-24 Impact factor: 4.089
Authors: Larissa Staurengo-Ferrari; Ivan J M Bonet; Dioneia Araldi; Paul G Green; Jon D Levine Journal: J Neurosci Date: 2021-12-08 Impact factor: 6.709
Authors: Christine Miaskowski; Kimberly Topp; Yvette P Conley; Steven M Paul; Michelle Melisko; Mark Schumacher; Margaret Chesney; Gary Abrams; Jon D Levine; Kord M Kober Journal: J Neuroimmunol Date: 2019-08-02 Impact factor: 3.478
Authors: Elizabeth K Lee; Zhenying Tan-Wasielewski; Ursula A Matulonis; Michael J Birrer; Alexi A Wright; Neil Horowitz; Panagiotis A Konstantinopoulos; Jennifer Curtis; Joyce F Liu Journal: Gynecol Oncol Rep Date: 2019-08-10
Authors: Petra Huehnchen; Christian Schinke; Nikola Bangemann; Adam D Dordevic; Johannes Kern; Smilla K Maierhof; Lois Hew; Luca Nolte; Peter Körtvelyessy; Jens C Göpfert; Klemens Ruprecht; Christopher J Somps; Jens-Uwe Blohmer; Jalid Sehouli; Matthias Endres; Wolfgang Boehmerle Journal: JCI Insight Date: 2022-03-22